Keywords:
Mesoblast (MESO) Announces Phase 3 Study Results of Rexlemestrocel-L in 565 New York Heart Association ((NYHA)) Class II and Class III Chronic Heart Failure Patients ...
CAMEROON MAGAZINE - GM15/11/20211 Mins read34 ViewsKeywords:
Objective To compare the long term efficacy and safety of rosuvastatin with...
ByCAMEROON MAGAZINE - GM19/10/2023(WISH) — A procedure called Ross is coming to the rescue for...
ByCAMEROON MAGAZINE - GM26/08/2023Graham had been in the hospital for a number of months dealing...
ByCAMEROON MAGAZINE - GM18/05/2023Home »Sector» Healthcare ASX Stocks »This is why Mesoblast (ASX: MSB) share...
ByCAMEROON MAGAZINE - GM14/12/2021